| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on July 24, 2003
From the Division of Clinical Pharmacology, Vanderbilt University School of Medicine, Nashville, Tenn. * To whom correspondence should be addressed. E-mail: michael.stein{at}vanderbilt.edu.
Abstract--Black Americans have a reduced hypotensive response to the
Revised on July 31, 2003
Alpha2-Adrenergic Receptor-Induced Vascular Constriction in Blacks and Whites
Mordechai Muszkat;
2-adrenergic receptor agonist clonidine compared with whites, despite similar central sympathoinhibition. This reduced hypotensive response might be explained by greater postsynaptic vascular
2-adrenergic receptor vasoconstrictive response. However, clonidine has a low
2/
1 selectivity ratio. Therefore, to determine the role of altered
2-adrenergic receptor vascular sensitivity in ethnic differences in vascular response, we compared local vascular responses with the highly selective
2-adrenergic receptor agonist dexmedetomidine in healthy black (n=18) and white (n=19) subjects. Increasing doses of dexmedetomidine (0.001 to 1000 ng/min) were infused into a dorsal hand vein, and the local response was measured with a linear variable differential transformer. Dexmedetomidine caused pronounced venoconstriction, with an average (±SD) maximum response of 74.5±17.72% but with no difference between blacks and whites. There was substantial intersubject variability in the sensitivity to dexmedetomidine; the dose resulting in 50% (ED50) of maximum vasoconstriction ranged from 0.08 ng/min to 256 ng/min. The geometric mean ED50 was 2.28 ng/min (95% CI, 0.02 to 271.6 ng/min) in blacks and 1.58 ng/min (95% CI, 0.11 to 24.55 ng/min) in whites (P=0.59). Our data indicate that
2-adrenergic receptor-induced venoconstriction is similar in blacks and whites. These findings do not support the hypothesis that altered
2-adrenergic receptor sensitivity is the explanation for the decreased blood pressure response to systemic administration of clonidine in blacks. The response to dexmedetomidine provides a model that will allow further study of the regulation of
2-adrenergic receptor-mediated vascular responses
This article has been cited by other articles:
![]() |
A. Snapir, P. Talke, J. Posti, M. Huiku, E. Kentala, and M. Scheinin Effects of nitric oxide synthase inhibition on dexmedetomidine-induced vasoconstriction in healthy human volunteers Br. J. Anaesth., January 1, 2009; 102(1): 38 - 46. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Kurnik, M. Muszkat, G. G. Sofowora, E. A. Friedman, W. D. Dupont, M. Scheinin, A. J.J. Wood, and C. M. Stein Ethnic and Genetic Determinants of Cardiovascular Response to the Selective {alpha}2-Adrenoceptor Agonist Dexmedetomidine Hypertension, February 1, 2008; 51(2): 406 - 411. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. C. Duling, T. W. Cherng, J. R. Griego, M. F. Perrine, and N. L. Kanagy Loss of {alpha}2B-adrenoceptors increases magnitude of hypertension following nitric oxide synthase inhibition Am J Physiol Heart Circ Physiol, November 1, 2006; 291(5): H2403 - H2408. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Masuki, F. A. Dinenno, M. J. Joyner, and J. H. Eisenach Selective {alpha}2-adrenergic properties of dexmedetomidine over clonidine in the human forearm J Appl Physiol, August 1, 2005; 99(2): 587 - 592. [Abstract] [Full Text] [PDF] |
||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2003 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |